                         SEQUENCE LISTING

<110>  BRISTOL-MYERS SQUIBB COMPANY
       NOVOTNY, JAMES  JR.
       LONGBERG, NILS
	 HEDVAT, CYRUS
       CLYNES, RAPHAEL
       LOCKE, DARREN
       COGSWELL, JOHN P.
       JACKSON, JEFFREY
	 HARBISON, CHRISTOPHER
       EDWARDS, ROBIN
	 
<120>  TREATMENT OF LAG-3 POSITIVE TUMORS

<130>  3338.070PC04/ELE/PAC/E-H

<150>  62/512,648
<151>  2017-05-30

<150>  62/513,813
<151>  2017-06-01

<150>  62/555,176
<151>  2017-09-07

<150>  62/582,178
<151>  2017-11-06

<160>  32    

<170>  PatentIn version 3.5

<210>  1
<211>  447
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Amino Acid Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  1

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Arg Gly Ser Thr Asn Ser Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 
        115                 120                 125             


Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 
    130                 135                 140                 


Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 
145                 150                 155                 160 


Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 
                165                 170                 175     


Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 
            180                 185                 190         


Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 
        195                 200                 205             


Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 
    210                 215                 220                 


Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 
225                 230                 235                 240 


Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 
                245                 250                 255     


Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 
            260                 265                 270         


Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 
        275                 280                 285             


Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 
    290                 295                 300                 


Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 
305                 310                 315                 320 


Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 
                325                 330                 335     


Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 
            340                 345                 350         


Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 
        355                 360                 365             


Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 
    370                 375                 380                 


Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 
385                 390                 395                 400 


Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 
                405                 410                 415     


Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 
            420                 425                 430         


His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440                 445         


<210>  2
<211>  214
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain Amino Acid Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  2

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
            180                 185                 190         


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
        195                 200                 205             


Phe Asn Arg Gly Glu Cys 
    210                 


<210>  3
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Variable Region (VH) Amino Acid Sequence; Anti-LAG-3 
       mAb (BMS-986016)

<400>  3

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Arg Gly Ser Thr Asn Ser Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  4
<211>  360
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Variable Region (VH) Nucleotide Sequence; Anti-LAG-3 
       mAb (BMS-986016)

<400>  4
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc       60

acctgcgctg tctatggtgg gtccttcagt gattactact ggaactggat ccgccagccc      120

ccagggaagg ggctggagtg gattggggaa atcaatcatc gtggaagcac caactccaac      180

ccgtccctca agagtcgagt caccctatca ctagacacgt ccaagaacca gttctccctg      240

aagctgaggt ctgtgaccgc cgcggacacg gctgtgtatt actgtgcgtt tggatatagt      300

gactacgagt acaactggtt cgacccctgg ggccagggaa ccctggtcac cgtctcctca      360


<210>  5
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain Variable Region (VL) Amino Acid Sequence; Anti-LAG-3 
       mAb (BMS-986016)

<400>  5

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile Lys 
            100                 105         


<210>  6
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Light Chain Variable Region (VL) Nucleotide Sequence; Anti-LAG-3 
       mAb (BMS-986016)

<400>  6
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc       60

ctctcctgca gggccagtca gagtattagc agctacttag cctggtacca acagaaacct      120

ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc      180

aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct      240

gaagattttg cagtttatta ctgtcagcag cgtagcaact ggcctctcac ttttggccag      300

gggaccaacc tggagatcaa a                                                321


<210>  7
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR1 Amino Acid Sequence; Anti-LAG-3 mAb 
       (BMS-986016)

<400>  7

Asp Tyr Tyr Trp Asn 
1               5   


<210>  8
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR2 Amino Acid Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  8

Glu Ile Asn His Arg Gly Ser Thr Asn Ser Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  9
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR3 Amino Acid Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  9

Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro 
1               5                   10          


<210>  10
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR1 Amino Acid Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  10

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR2 Amino Acid Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  11

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR3 Amino Acid Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  12

Gln Gln Arg Ser Asn Trp Pro Leu Thr 
1               5                   


<210>  13
<211>  525
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Human LAG-3 Amino Acid Sequence

<400>  13

Met Trp Glu Ala Gln Phe Leu Gly Leu Leu Phe Leu Gln Pro Leu Trp 
1               5                   10                  15      


Val Ala Pro Val Lys Pro Leu Gln Pro Gly Ala Glu Val Pro Val Val 
            20                  25                  30          


Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile 
        35                  40                  45              


Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln 
    50                  55                  60                  


His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu 
65                  70                  75                  80  


Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro 
                85                  90                  95      


Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly 
            100                 105                 110         


Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln 
        115                 120                 125             


Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala 
    130                 135                 140                 


Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys 
145                 150                 155                 160 


Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro 
                165                 170                 175     


Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser 
            180                 185                 190         


Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln 
        195                 200                 205             


Gly Arg Val Pro Val Arg Glu Ser Pro His His His Leu Ala Glu Ser 
    210                 215                 220                 


Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly 
225                 230                 235                 240 


Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn 
                245                 250                 255     


Leu Thr Val Leu Gly Leu Glu Pro Pro Thr Pro Leu Thr Val Tyr Ala 
            260                 265                 270         


Gly Ala Gly Ser Arg Val Gly Leu Pro Cys Arg Leu Pro Ala Gly Val 
        275                 280                 285             


Gly Thr Arg Ser Phe Leu Thr Ala Lys Trp Thr Pro Pro Gly Gly Gly 
    290                 295                 300                 


Pro Asp Leu Leu Val Thr Gly Asp Asn Gly Asp Phe Thr Leu Arg Leu 
305                 310                 315                 320 


Glu Asp Val Ser Gln Ala Gln Ala Gly Thr Tyr Thr Cys His Ile His 
                325                 330                 335     


Leu Gln Glu Gln Gln Leu Asn Ala Thr Val Thr Leu Ala Ile Ile Thr 
            340                 345                 350         


Val Thr Pro Lys Ser Phe Gly Ser Pro Gly Ser Leu Gly Lys Leu Leu 
        355                 360                 365             


Cys Glu Val Thr Pro Val Ser Gly Gln Glu Arg Phe Val Trp Ser Ser 
    370                 375                 380                 


Leu Asp Thr Pro Ser Gln Arg Ser Phe Ser Gly Pro Trp Leu Glu Ala 
385                 390                 395                 400 


Gln Glu Ala Gln Leu Leu Ser Gln Pro Trp Gln Cys Gln Leu Tyr Gln 
                405                 410                 415     


Gly Glu Arg Leu Leu Gly Ala Ala Val Tyr Phe Thr Glu Leu Ser Ser 
            420                 425                 430         


Pro Gly Ala Gln Arg Ser Gly Arg Ala Pro Gly Ala Leu Pro Ala Gly 
        435                 440                 445             


His Leu Leu Leu Phe Leu Thr Leu Gly Val Leu Ser Leu Leu Leu Leu 
    450                 455                 460                 


Val Thr Gly Ala Phe Gly Phe His Leu Trp Arg Arg Gln Trp Arg Pro 
465                 470                 475                 480 


Arg Arg Phe Ser Ala Leu Glu Gln Gly Ile His Pro Pro Gln Ala Gln 
                485                 490                 495     


Ser Lys Ile Glu Glu Leu Glu Gln Glu Pro Glu Pro Glu Pro Glu Pro 
            500                 505                 510         


Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Gln Leu 
        515                 520                 525 


<210>  14
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LAG-3 Epitope

<400>  14

Pro Gly His Pro Leu Ala Pro Gly 
1               5               


<210>  15
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LAG-3 Epitope

<400>  15

His Pro Ala Ala Pro Ser Ser Trp 
1               5               


<210>  16
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LAG-3 Epitope

<400>  16

Pro Ala Ala Pro Ser Ser Trp Gly 
1               5               


<210>  17
<211>  440
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  17

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser 
        115                 120                 125             


Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 
    130                 135                 140                 


Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 
145                 150                 155                 160 


Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 
                165                 170                 175     


Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys 
            180                 185                 190         


Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp 
        195                 200                 205             


Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala 
    210                 215                 220                 


Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
225                 230                 235                 240 


Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 
                245                 250                 255     


Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val 
            260                 265                 270         


Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 
        275                 280                 285             


Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 
    290                 295                 300                 


Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 
305                 310                 315                 320 


Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 
                325                 330                 335     


Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr 
            340                 345                 350         


Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 
        355                 360                 365             


Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 
    370                 375                 380                 


Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 
385                 390                 395                 400 


Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe 
                405                 410                 415     


Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 
            420                 425                 430         


Ser Leu Ser Leu Ser Leu Gly Lys 
        435                 440 


<210>  18
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  18

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
        115                 120                 125             


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
    130                 135                 140                 


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
145                 150                 155                 160 


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
                165                 170                 175     


Ser Thr Leu Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 
            180                 185                 190         


Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 
        195                 200                 205             


Asn Arg Gly Glu Cys 
    210             


<210>  19
<211>  113
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Variable Region (VH) Amino Acid Sequence; Anti-PD-1 
       mAb (BMS936558)

<400>  19

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  20
<211>  339
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Variable Region (VH) Nucleotide Sequence; Anti-PD-1 
       mAb (BMS936558)

<400>  20
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc       60

gactgtaaag cgtctggaat caccttcagt aactctggca tgcactgggt ccgccaggct      120

ccaggcaagg ggctggagtg ggtggcagtt atttggtatg atggaagtaa aagatactat      180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgttt      240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gacaaacgac      300

gactactggg gccagggaac cctggtcacc gtctcctca                             339


<210>  21
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain Variable Region (VL) Amino Acid Sequence; Anti-PD-1 
       mAb (BMS936558)

<400>  21

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  22
<211>  321
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Light Chain Variable Region (VL) Nucleotide Sequence; Anti-PD-1 
       mAb (BMS936558)

<400>  22
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc       60

ctctcctgca gggccagtca gagtgttagt agttacttag cctggtacca acagaaacct      120

ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc      180

aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct      240

gaagattttg cagtttatta ctgtcagcag agtagcaact ggcctcggac gttcggccaa      300

gggaccaagg tggaaatcaa a                                                321


<210>  23
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR1 Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  23

Asn Ser Gly Met His 
1               5   


<210>  24
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR2 Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  24

Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  25
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy Chain CDR3 Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  25

Asn Asp Asp Tyr 
1               


<210>  26
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR1 Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  26

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  27
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR2 Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  27

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light Chain CDR3 Amino Acid Sequence; Anti-PD-1 mAb (BMS936558)

<400>  28

Gln Gln Ser Ser Asn Trp Pro Arg Thr 
1               5                   


<210>  29
<211>  2106
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Complete Homo sapiens PD-1 sequence

<400>  29
agtttccctt ccgctcacct ccgcctgagc agtggagaag gcggcactct ggtggggctg       60

ctccaggcat gcagatccca caggcgccct ggccagtcgt ctgggcggtg ctacaactgg      120

gctggcggcc aggatggttc ttagactccc cagacaggcc ctggaacccc cccaccttct      180

tcccagccct gctcgtggtg accgaagggg acaacgccac cttcacctgc agcttctcca      240

acacatcgga gagcttcgtg ctaaactggt accgcatgag ccccagcaac cagacggaca      300

agctggccgc cttccccgag gaccgcagcc agcccggcca ggactgccgc ttccgtgtca      360

cacaactgcc caacgggcgt gacttccaca tgagcgtggt cagggcccgg cgcaatgaca      420

gcggcaccta cctctgtggg gccatctccc tggcccccaa ggcgcagatc aaagagagcc      480

tgcgggcaga gctcagggtg acagagagaa gggcagaagt gcccacagcc caccccagcc      540

cctcacccag gccagccggc cagttccaaa ccctggtggt tggtgtcgtg ggcggcctgc      600

tgggcagcct ggtgctgcta gtctgggtcc tggccgtcat ctgctcccgg gccgcacgag      660

ggacaatagg agccaggcgc accggccagc ccctgaagga ggacccctca gccgtgcctg      720

tgttctctgt ggactatggg gagctggatt tccagtggcg agagaagacc ccggagcccc      780

ccgtgccctg tgtccctgag cagacggagt atgccaccat tgtctttcct agcggaatgg      840

gcacctcatc ccccgcccgc aggggctcag ccgacggccc tcggagtgcc cagccactga      900

ggcctgagga tggacactgc tcttggcccc tctgaccggc ttccttggcc accagtgttc      960

tgcagaccct ccaccatgag cccgggtcag cgcatttcct caggagaagc aggcagggtg     1020

caggccattg caggccgtcc aggggctgag ctgcctgggg gcgaccgggg ctccagcctg     1080

cacctgcacc aggcacagcc ccaccacagg actcatgtct caatgcccac agtgagccca     1140

ggcagcaggt gtcaccgtcc cctacaggga gggccagatg cagtcactgc ttcaggtcct     1200

gccagcacag agctgcctgc gtccagctcc ctgaatctct gctgctgctg ctgctgctgc     1260

tgctgctgcc tgcggcccgg ggctgaaggc gccgtggccc tgcctgacgc cccggagcct     1320

cctgcctgaa cttgggggct ggttggagat ggccttggag cagccaaggt gcccctggca     1380

gtggcatccc gaaacgccct ggacgcaggg cccaagactg ggcacaggag tgggaggtac     1440

atggggctgg ggactcccca ggagttatct gctccctgca ggcctagaga agtttcaggg     1500

aaggtcagaa gagctcctgg ctgtggtggg cagggcagga aacccctccc acctttacac     1560

atgcccaggc agcacctcag gccctttgtg gggcagggaa gctgaggcag taagcgggca     1620

ggcagagctg gaggcctttc aggccagcca gcactctggc ctcctgccgc cgcattccac     1680

cccagcccct cacaccactc gggagaggga catcctacgg tcccaaggtc aggagggcag     1740

ggctggggtt gactcaggcc cctcccagct gtggccacct gggtgttggg agggcagaag     1800

tgcaggcacc tagggccccc catgtgccca ccctgggagc tctccttgga acccattcct     1860

gaaattattt aaaggggttg gccgggctcc caccagggcc tgggtgggaa ggtacaggcg     1920

ttcccccggg gcctagtacc cccgcgtggc ctatccactc ctcacatcca cacactgcac     1980

ccccactcct ggggcagggc caccagcatc caggcggcca gcaggcacct gagtggctgg     2040

gacaagggat cccccttccc tgtggttcta ttatattata attataatta aatatgagag     2100

catgct                                                                2106


<210>  30
<211>  1344
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Heavy Chain Nucleotide Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  30
caggtgcagc tacagcagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc       60

acctgcgctg tctatggtgg gtccttcagt gattactact ggaactggat ccgccagccc      120

ccagggaagg ggctggagtg gattggggaa atcaatcatc gtggaagcac caactccaac      180

ccgtccctca agagtcgagt caccctatca ctagacacgt ccaagaacca gttctccctg      240

aagctgaggt ctgtgaccgc cgcggacacg gctgtgtatt actgtgcgtt tggatatagt      300

gactacgagt acaactggtt cgacccctgg ggccagggaa ccctggtcac cgtctcctca      360

gctagcacca agggcccatc cgtcttcccc ctggcgccct gctccaggag cacctccgag      420

agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg      480

tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca      540

ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc      600

tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc      660

aaatatggtc ccccatgccc accatgccca gcacctgagt tcctgggggg accatcagtc      720

ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg      780

tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat      840

ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa cagcacgtac      900

cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag      960

tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa     1020

gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag     1080

aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag     1140

tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc     1200

gacggctcct tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg     1260

aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc     1320

ctctccctgt ctctgggtaa atga                                            1344


<210>  31
<211>  645
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Light Chain Nucleotide Sequence; Anti-LAG-3 mAb (BMS-986016)

<400>  31
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc       60

ctctcctgca gggccagtca gagtattagc agctacttag cctggtacca acagaaacct      120

ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc      180

aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct      240

gaagattttg cagtttatta ctgtcagcag cgtagcaact ggcctctcac ttttggccag      300

gggaccaacc tggagatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca      360

tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat      420

cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag      480

gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg      540

ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc      600

ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag                      645


<210>  32
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Motif

<400>  32

Met Tyr Pro Pro Pro Tyr 
1               5       


